Hypothalamic obesity… What is the hypothalamus? Deep in the center of your brain is a small but powerful structure called the hypothalamus. Think of it as your body's control center. It manages many critical functions that keep you alive and healthy, including: Appetite and metabolism (telling you when you're hungry and when you're full, and how fast your body burns energy); Body temperature (keeping you at the right temperature); Sleep-wake cycles (helping you feel awake during the day and sleepy at night); Water balance (controlling thirst and how much water your body holds onto); Hormone production (directing the pituitary gland, which in turn controls your thyroid, adrenal glands, sex hormones, growth hormone, and more). What is hypothalamic obesity? Sometimes the hypothalamus is severely damaged, most often by a brain tumor (such as a craniopharyngioma) or by the surgery and radiation used to treat that tumor. When this happens, the nerve cells that normally regulate appetite and metabolism stop working properly. This leads to: Insatiable hunger (hyperphagia, a constant, overwhelming drive to eat that is not a matter of willpower). The brain's "fullness signal" is broken. Reduced energy burning (the body's metabolic rate slows down significantly). Rapid and severe weight gain which can lead to obesity and all of its related health risks, including diabetes, heart disease, and more. This condition is called hypothalamic obesity. It is fortunately rare, but for those who have it, standard weight-loss approaches — diet, exercise, and even many medications (including GLPs) often fall short because they don't fix the specific broken pathway in the brain. In a healthy brain, the hypothalamus sends a chemical signal called alpha-MSH to a receptor (called MC4R) that tells your body "you're full — stop eating" and "burn more energy." In hypothalamic obesity, the damaged hypothalamus can no longer produce this signal properly. Setmelanotide is a medication that acts like a stand-in for that missing signal. It skips over the damaged part of the hypothalamus and directly activates the MC4R receptor downstream. You can think of it like a detour around a roadblock as the medication delivers the "fullness" message that the injured hypothalamus can no longer send on its own. In many ways, it is similar to how patients with hypothalamic injury already take replacement hormones (like thyroid hormone or cortisol) to substitute for what the damaged hypothalamus and pituitary can no longer produce. A major clinical trial called TRANSCEND, published in the @NEJM yesterday, tested setmelanotide against a placebo (inactive injection) in 120 patients aged 4 to 66 with hypothalamic obesity. The results after one year were striking: Patients on setmelanotide had an average 16.5% reduction in BMI, while those on placebo saw their BMI increase slightly. 83% of patients on setmelanotide achieved a meaningful reduction in body weight. Hunger scores improved significantly — patients reported feeling less driven to eat. The most common side effects included: Skin darkening (hyperpigmentation) Nausea and vomiting and headaches. What does this mean for patients? This is an important milestone for a condition that has historically been very difficult to treat. A long-term extension study is ongoing to understand the benefits and safety beyond one year. If you or a loved one has concerns about potential hypothalamic obesity, talk to your endocrinologist (who likely cares for the pituitary deficiencies) or primary care first. #obesity #hormones #peptides #weightloss #hunger